Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives
Zhiyi Ye,
No information about this author
Pu Cheng,
No information about this author
Qi Huang
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: May 22, 2024
The
tumor
microenvironment
is
closely
linked
to
the
initiation,
promotion,
and
progression
of
solid
tumors.
Among
its
constitutions,
immunologic
cells
emerge
as
critical
players,
facilitating
immune
evasion
progression.
Apart
from
their
indirect
impact
on
anti-tumor
immunity,
immunocytes
directly
influence
neoplastic
cells,
either
bolstering
or
impeding
advancement.
However,
current
therapeutic
modalities
aimed
at
alleviating
immunosuppression
regulatory
effector
cell
populations
may
not
consistently
yield
satisfactory
results
in
various
tumors,
such
breast
carcinoma,
colorectal
cancer,
etc.
Therefore,
this
review
outlines
summarizes
direct,
dualistic
effects
T
innate
lymphoid
B
eosinophils,
tumor-associated
macrophages
within
microenvironment.
also
delves
into
underlying
mechanisms
involved
presents
outcomes
clinical
trials
based
these
direct
effects,
aiming
propose
innovative
efficacious
strategies
for
addressing
Language: Английский
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Neoplasia,
Journal Year:
2025,
Volume and Issue:
61, P. 101137 - 101137
Published: Feb. 10, 2025
Language: Английский
Supercharging CAR-T cells through transcriptional and epigenetic armoring
Diyuan Qin,
No information about this author
Yanna Lei,
No information about this author
Pei Shu
No information about this author
et al.
Theranostics,
Journal Year:
2025,
Volume and Issue:
15(8), P. 3345 - 3367
Published: Feb. 18, 2025
Inspired
by
the
remarkable
success
of
CAR-T
therapy
in
hematologic
malignancies,
research
is
increasingly
focused
on
adapting
this
treatment
for
solid
tumors.
However,
efficacy
remains
limited
due
to
its
exhaustion
and
shortened
persistence.
Transcription
factors
epigenetic
modifications
play
pivotal
roles
modulating
T
cell
differentiation
functionality,
which
have
been
leveraged
numerous
strategies
promote
formation
long-lasting
memory
cells
with
stem-like
properties
supercharging
performance.
This
review
highlights
transcriptional
factors,
such
as
c-Jun
FOXO1,
enhance
sustain
effector
function,
diminishes
exhaustion,
regulators
like
TET2
DNMT3A,
whose
knockout
promotes
subsets
formation.
We
explore
their
interconnections,
downstream
targets,
biological
impacts,
potential
application
risks
certain
candidates,
providing
a
comprehensive
theoretical
framework
therapies
through
interventions.
Language: Английский
Towards precision medicine strategies using plasma proteomic profiling for suspected gallbladder cancer: a pilot study
JHEP Reports,
Journal Year:
2025,
Volume and Issue:
unknown, P. 101365 - 101365
Published: Feb. 1, 2025
Language: Английский
STAT3 Signaling Pathway in Health and Disease
MedComm,
Journal Year:
2025,
Volume and Issue:
6(4)
Published: March 30, 2025
ABSTRACT
Signal
transducer
and
activator
of
transcription
3
(STAT3)
is
a
critical
factor
involved
in
multiple
physiological
pathological
processes.
While
STAT3
plays
an
essential
role
homeostasis,
its
persistent
activation
has
been
implicated
the
pathogenesis
various
diseases,
particularly
cancer,
bone‐related
autoimmune
disorders,
inflammatory
cardiovascular
neurodegenerative
conditions.
The
interleukin‐6/Janus
kinase
(JAK)/STAT3
signaling
axis
central
to
activation,
influencing
tumor
microenvironment
remodeling,
angiogenesis,
immune
evasion,
therapy
resistance.
Despite
extensive
research,
precise
mechanisms
underlying
dysregulated
disease
progression
remain
incompletely
understood,
no
United
States
Food
Drug
Administration
(USFDA)‐approved
direct
inhibitors
currently
exist.
This
review
provides
comprehensive
evaluation
STAT3's
health
disease,
emphasizing
involvement
cancer
stem
cell
maintenance,
metastasis,
inflammation,
drug
We
systematically
discuss
therapeutic
strategies,
including
JAK
(tofacitinib,
ruxolitinib),
Src
Homology
2
domain
(S3I‐201,
STATTIC),
antisense
oligonucleotides
(AZD9150),
nanomedicine‐based
delivery
systems,
which
enhance
specificity
bioavailability
while
reducing
toxicity.
By
integrating
molecular
mechanisms,
pathology,
emerging
interventions,
this
fills
knowledge
gap
STAT3‐targeted
therapy.
Our
insights
into
crosstalk,
epigenetic
regulation,
resistance
offer
foundation
for
developing
next‐generation
with
greater
clinical
efficacy
translational
potential.
Language: Английский
B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer
iScience,
Journal Year:
2024,
Volume and Issue:
27(10), P. 110889 - 110889
Published: Sept. 6, 2024
Language: Английский
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms
Clinical Cancer Research,
Journal Year:
2024,
Volume and Issue:
30(20), P. 4554 - 4556
Published: Aug. 7, 2024
The
transcription
factor
STAT3
drives
the
expression
of
genes
promoting
cellular
proliferation,
survival,
and
pluripotency.
description
mutations
their
clinical
correlates
in
myeloid
neoplasms,
such
as
acute
leukemia
myelodysplastic
syndromes,
raises
new
insights
into
both
pathogenesis
targeted
therapy
these
diseases.
See
related
article
by
Ye
et
al.,
p.
4681.
Language: Английский